Pfizer India
- All
- News
- Videos
-
2 Indian-Origin People Charged In US With Insider Trading With Pfizer Covid-19 Medicine
In a parallel action, the US Attorney's Office for the Southern District of New York also announced criminal charges against the duo.
-
Pfizer Names Meenakshi Nevatia As Managing Director
Drug maker Pfizer Ltd on Thursday said it has appointed Meenakshi Nevatia as managing director for a period of five years with effect from April 3, 2023.
-
Government Blocked Pfizer's Covid Vaccine, Claims KCR In New Attack
Telangana Chief Minister K Chandrashekar Rao has alleged that the Central government did everything possible to "forcefully" prevent import of COVID-19 vaccines from Pfizer, especially when people were ready to get the best vaccine.
-
Drug Firm Pfizer's Managing Director S Sridhar Resigns To Take Early Retirement
Drug firm Pfizer on Wednesday said its Managing Director S Sridhar has resigned from the company.
-
Made In India Covid Vaccines Better Than Pfizer, Moderna, Says Adar Poonawalla: Report
Serum Institute of India (SII) CEO Adar Poonawalla today claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.
-
US Authorizes Pfizer COVID-19 Booster Shot For Children As Young As 12
US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.
-
Booster Dose Of 6 Covid Vaccines Safe, Increases Immunity: Lancet Study
Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines, according to a study published in The Lancet journal.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Pfizer Vaccine Highly Effective Against COVID-19 Hospitalisations For 6 Months: Lancet Study
Two doses of the Pfizer COVID-19 vaccine are 90 per cent effective against hospitalisation from the disease for all variants, including Delta, for at least six months, according to a study published in The Lancet journal on Tuesday.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
80% Covid Immunity Lost In 6 Months In Some After Pfizer Jab: US Study
COVID-19 antibodies produced by the Pfizer vaccine decreased more than 80 per cent in senior nursing home residents and their caregivers six months after receiving their second dose, a US study has found.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
-
2 Indian-Origin People Charged In US With Insider Trading With Pfizer Covid-19 Medicine
In a parallel action, the US Attorney's Office for the Southern District of New York also announced criminal charges against the duo.
-
Pfizer Names Meenakshi Nevatia As Managing Director
Drug maker Pfizer Ltd on Thursday said it has appointed Meenakshi Nevatia as managing director for a period of five years with effect from April 3, 2023.
-
Government Blocked Pfizer's Covid Vaccine, Claims KCR In New Attack
Telangana Chief Minister K Chandrashekar Rao has alleged that the Central government did everything possible to "forcefully" prevent import of COVID-19 vaccines from Pfizer, especially when people were ready to get the best vaccine.
-
Drug Firm Pfizer's Managing Director S Sridhar Resigns To Take Early Retirement
Drug firm Pfizer on Wednesday said its Managing Director S Sridhar has resigned from the company.
-
Made In India Covid Vaccines Better Than Pfizer, Moderna, Says Adar Poonawalla: Report
Serum Institute of India (SII) CEO Adar Poonawalla today claimed that "Made in India" COVID-19 vaccines have provided more protection against the coronavirus infection than mRNA vaccines like Pfizer and Moderna.
-
US Authorizes Pfizer COVID-19 Booster Shot For Children As Young As 12
US health authorities on Monday approved Pfizer's Covid-19 booster shot for children as young as 12, and reduced the wait time between initial vaccination and an extra dose from six months to five, for all ages.
-
Booster Dose Of 6 Covid Vaccines Safe, Increases Immunity: Lancet Study
Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines, according to a study published in The Lancet journal.
-
Dr Reddy's Open To Making Pfizer Covid Pill
Dr Reddy's Laboratories, one of a handful of Indian drug companies licensed to make a new COVID-19 pill developed by Merck, said on Monday it was open to making a similar pill from Pfizer, thought to be even more effective.
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Covid Poses Higher Risk Of Rare Brain Conditions Than Vaccines: Oxford-Led Study
COVID-19 is more likely to cause very rare neurological conditions than vaccination with the AstraZeneca or Pfizer preventives, according to a study led by the University of Oxford in the UK.
-
Pfizer Vaccine Highly Effective Against COVID-19 Hospitalisations For 6 Months: Lancet Study
Two doses of the Pfizer COVID-19 vaccine are 90 per cent effective against hospitalisation from the disease for all variants, including Delta, for at least six months, according to a study published in The Lancet journal on Tuesday.
-
Government Won't Buy Pfizer, Moderna Shots As Local Output Jumps: Report
India will not buy COVID-19 shots from Pfizer/BioNTech and Moderna, three government sources told Reuters, mainly because domestic output of more affordable and easier-to-store vaccines has jumped.
-
UK Schoolchildren Aged 12-15 Years To Be Offered Covid Vaccine First Dose
Schoolchildren aged between 12 and 15 years will be offered a first dose of the Pfizer/BioNTech COVID-19 vaccine starting next week, the UK government has announced after the country's Chief Medical Officers gave their go-ahead for the jabs for young
-
80% Covid Immunity Lost In 6 Months In Some After Pfizer Jab: US Study
COVID-19 antibodies produced by the Pfizer vaccine decreased more than 80 per cent in senior nursing home residents and their caregivers six months after receiving their second dose, a US study has found.
-
COVID-19 Has More Blood Clot Threat Than Vaccines, Says UK Study: Report
A coronavirus infection presents a much higher risk of developing a blood clot than the first dose of either the Oxford/AstraZeneca or the Pfizer/BioNTech jab, a large study led by the University of Oxford said on Friday.
